Patent · US Active

Gene therapy for treating mucopolysaccharidosis type II

US11253612B2 · kind B2 · utility

1Cited by
53References
24Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 14, 2017
Grant dateFeb 22, 2022
Priority date
Expiry dateNov 3, 2038

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2830/15
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A suspension useful for AAV9-mediated intrathecal and/or systemic delivery of an expression cassette containing a hIDS gene is provided herein. Also provided are methods and kits containing these vectors and compositions useful for treating Hunter syndrome and the symptoms associated with Hunter syndrome.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.